Skip to main content
221 search results for:

Tirzepatide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 09-05-2024 | Online First

    Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

    Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus …

  2. Open Access 01-12-2024 | Tirzepatide | OriginalPaper

    Evidence that tirzepatide protects against diabetes-related cardiac damages

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used antidiabetic drugs, are approved and recommended in several treatment guidelines for reducing the risk of major adverse cardiovascular events (MACE), such as cardiovascular death …

  3. Open Access 08-05-2024 | Tirzepatide | Online First

    Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective

    The use of disease or multi-use models (i.e. one model that can be used to determine the cost effectiveness of many new technologies in a certain disease) is increasingly being advocated [ 1 – 3 ]. Diabetes is a disease area where such models are …

  4. 23-02-2024 | Tirzepatide | ReviewPaper

    Tirzepatide: A Review in Type 2 Diabetes

    Tirzepatide (Mounjaro®), a first-in-class dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is approved for use as an adjunct to diet and exercise to improve glycaemic …

  5. Open Access 18-03-2024 | Tirzepatide | OriginalPaper

    Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups

    In recent years, there has been epidemic growth in the number of individuals with diabetes worldwide, increasing from 422 million in 2014 to 529 million in 2021 [ 1 , 2 ], primarily attributed to the escalating prevalence of type 2 diabetes (T2D) [ …3

  6. 02-03-2024 | Tirzepatide | OriginalPaper

    Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study

    Metabolic and bariatric surgery (MBS) is the most effective treatment for obesity and improvement of obesity-associated comorbidities [ 1 ]. However, a proportion of these patients may suffer from weight recurrence and recurrence of …

  7. Open Access 13-04-2024 | Tirzepatide | Online First

    Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

    Semaglutide, administered s.c., has shown superior efficacy compared with other glucose-lowering agents, including its oral formulation, in reducing HbA 1c and in facilitating weight loss in individuals with type 2 diabetes [ 1 , 2 ]. Initially …

  8. Open Access 01-12-2024 | Tirzepatide | OriginalPaper

    Tirzepatide prevents neurodegeneration through multiple molecular pathways

    Alzheimer's disease (AD) is multi-factorial, with genetic and environmental factors implicated in its pathogenesis [ 1 ]. The best-described risk factors for AD are age, a positive family history of dementia, low levels of education, female gender …

  9. 25-03-2024 | Type 2 Diabetes | Online First

    Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials

    Various physiological characteristics, including excess body fat, insulin resistance, reduced insulin secretion, diminished incretin action, heightened glucagon release, and abnormal lipid levels, are key indicators of diabetes mellitus type 2 …

  10. Open Access 24-02-2024 | Tirzepatide | OriginalPaper

    Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    The global incidence of diabetes has experienced a significant surge in recent times and is projected to reach 700 million individuals (constituting 10.9% of the global population aged 20–79) by 2045 if effective interventions are not implemented …

  11. Open Access 24-01-2024 | Liraglutide | OriginalPaper

    Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database

    Healthcare professionals should be aware of the potential for psychiatric adverse events, particularly depression, anxiety and suicidal ideation associated with semaglutide, liraglutide, and tirzepatide. Patients should be encouraged to report any …

  12. Open Access 04-02-2024 | Tirzepatide | OriginalPaper

    Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis

    Based on data collected via the National Health and Nutrition Survey, mean body mass index (BMI) has significantly increased over the past two decades in Japan, and the prevalence of both type 2 diabetes (T2D) and obesity has steadily increased …

  13. Open Access 01-12-2024 | Tirzepatide | OriginalPaper

    Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

    In his 1988 Banting lecture, Reaven [ 1 ] referred to “Syndrome X” as the presence of insulin resistance, hyperglycemia, hyperinsulinemia, increased plasma concentration of very low-density lipoprotein (VLDL) triglyceride, decreased plasma …

  14. 01-12-2023 | Tirzepatide | News

    Tirzepatide

    Acute kidney injury and ileus
  15. 01-12-2023 | Tirzepatide | News

    Tirzepatide

    Small bowel obstruction: case report
  16. 01-10-2023 | Tirzepatide | News

    Tirzepatide

    Large bowel obstruction: case report
  17. 01-09-2023 | Ketoacidosis | News

    Tirzepatide

    Starvation ketoacidosis and electrolyte abnormalities due to nausea and vomiting: case report
  18. 14-11-2023 | Obesity | News | Article

    Tirzepatide approved for chronic obesity by FDA, MHRA 

    Once-weekly tirzepatide may be used alongside diet and exercise to treat chronic obesity, regulatory bodies in the USA and UK have announced.

  19. Open Access 01-08-2023 | Dulaglutid | ReviewPaper

    Beyond glycemia: Comparing tirzepatide to GLP-1 analogues

    Glucagon-like peptide-1 receptor analogs (GLP-1 RAs) have been an innovative and instrumental drug class in the management of both type 2 diabetes and obesity. Tirzepatide is a novel agent that acts as an agonist for both GLP-1 receptors and …

  20. Open Access 01-12-2023 | Insulin Glargine | OriginalPaper

    Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

    Hypertension is a common comorbidity of type 2 diabetes (T2D) and is twice as prevalent in people with T2D compared with those without T2D [ 1 ]. Approximately half of adults with hypertension are unaware they have it and, of those with …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.